News and Announcements
Altech Optimises Kaolin Beneficiation Plant Location
- Published November 26, 2015 11:40AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th November 2015, ASX Announcement
Highlights:
- Kaolin benefication plant to be located at the Company’s HPA plant site in Johor, Malaysia
- Lower capital and operating costs for kaolin benefication
- Detailed design and optimisation work continues
Altech Chemicals Limited (Altech/the Company) (ASX: ATC) is pleased to provide an update on the detailed design work that is currently underway for its proposed high purity alumnia (HPA) project. Detailed design commenced in September 2015, following the appointment of General Manager Operations Dr Jingyuan Liu and is being undertaken with the assistance of Simulus Engineering, a Perth based multidiscipline engineering consultancy and M+W Group, the EPCM contractor for the Project.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
